Consequently, this scaffold‐mediated co‐delivery of tumor‐specific CAR T cells along with c‐di‐GMP triggered robust antitumor immune responses in both pancreatic and melanoma models and led to sustained immunity against tumor rechallenge.[107] These studies established a foundation for combining STING agonists with CAR T cell therapy, providing preclinical evidence to support the exploration of this synergistic approach in solid tumor treatment for clinical settings. This evidence concerns the gene STING1 and melanoma.